A 26-week tolerability study of ciclesonide nasal aerosol in patients with perennial allergic rhinitis

American Journal of Rhinology and Allergy

Volumn 26, Issue 4, 2012, Pages 302-307

  Berger, William E ^a   Mohar, Dale E ^b   LaForce, Craig ^c   Raphael, Gordon ^d   Desai, Shailesh Y ^e   Huang, Holly ^e   Hinkle, Joseph ^e  

^a Allergy & Asthma Associates of Northern California   (United States)

^b Kerrville Research Associates   (United States)

^c North Carolina Clinical Research   (United States)

^d AsthmaAllergy and Clinical Research   (United States)

^e DAINIPPON SUMITOMO PHARMA CO LTD   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CICLESONIDE; PLACEBO;

ADULT; AEROSOL; APPLICATION SITE DISCOMFORT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY NOSE; EPISTAXIS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; MUCOSAL DISEASE; MULTICENTER STUDY; PARALLEL DESIGN; PERENNIAL RHINITIS; PHASE 3 CLINICAL TRIAL; QUALITY OF LIFE; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SINUSITIS; UPPER RESPIRATORY TRACT INFECTION;

ADULT; ANTI-ALLERGIC AGENTS; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; NASAL SPRAYS; PREGNENEDIONES; QUALITY OF LIFE; RHINITIS, ALLERGIC, PERENNIAL;

EID: 84864120570     PISSN: 19458924     EISSN: 19458932     Source Type: Journal    
DOI: 10.2500/ajra.2012.26.3773     Document Type: Article

References (24)

1. Greiner AN, Hellings PW, Rotiroti G, and Scadding GK. Allergic rhinitis. Lancet 378:2112-2122, 2011.
2. Meltzer EO, Nathan R, Derebery J, et al. Sleep, quality of life, and productivity impact of nasal symptoms in the United States: findings from the Burden of Rhinitis in America survey. Allergy Asthma Proc 3:244-254, 2009.
3. Blaiss MS. Allergic rhinitis: direct and indirect costs. Allergy Asthma Proc 31:375-380, 2010.
4. Meltzer EO, and Bukstein DA. The economic impact of allergic rhinitis and current guidelines for treatment. Ann Allergy Asthma Immunol 106(Suppl 2):S12-S16, 2011.
5. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: An updated practice parameter. J Allergy Clin Immunol (Suppl 2):S1-S84, 2008. (Pubitemid 352033573)
6. Sur DK, and Scandale S. Treatment of allergic rhinitis. Am Fam Physician 12:1440-1446, 2010.
7. Mutch E, Nave R, McCracken N, et al. The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol 73:1657-1664, 2007. (Pubitemid 46527549)
8. Neffen H, and Wingertzahn MA. Ciclesonide, a hypotonic intranasal corticosteroid. Allergy Asthma Proc 31;Suppl 1[May-June]:S29-S37, 2010.
9. Ratner PH, Wingertzahn MA, van Bavel JH, et al. Efficacy and safety of ciclesonide nasal spray for the treatment of seasonal allergic rhinitis. J Allergy Clin Immunol 118:1142-1148, 2006. (Pubitemid 44755181)
10. Meltzer EO, Kunjibettu S, Hall N, et al. Efficacy and safety of ciclesonide, 200 microg once daily, for the treatment of perennial allergic rhinitis. Ann Allergy Asthma Immunol 98:175-181, 2007. (Pubitemid 46214225)
11. Chervinsky P, Kunjibettu S, Miller DL, et al. Long-term safety and efficacy of intranasal ciclesonide in adult and adolescent patients with perennial allergic rhinitis. Ann Allergy Asthma Immunol 99:69-76, 2007. (Pubitemid 47075954)
12. Sunovion Pharmaceuticals, Inc. Omnaris prescribing information. Marlborough, MA; 2010.
13. Nave R, Herzog R, Laurent A, and Wingertzahn MA. Pharmacokinetics of ciclesonide and desisobutyryl ciclesonide after administration via aqueous nasal spray or hydrofluoroalkane nasal aerosol compared with orally inhaled ciclesonide: an open-label, single-dose, three-period crossover study in healthy volunteers. Clin Ther 12:2988-2999, 2009.
14. Ratner P, Wingertzahn MA, Herzog R, et al. An investigation of the pharmacokinetics, pharmacodynamics, safety, and tolerability of ciclesonide hydrofluoroalkane nasal aerosol in healthy subjects and subjects with perennial allergic rhinitis. Pulm Pharmacol Ther 24:426-433, 2011.
15. Ratner PH, Andrews C, Martin B, et al. A study of the efficacy and safety of ciclesonide hydrofluoroalkane nasal aerosol for the treatment of seasonal allergic rhinitis to Mountain Cedar pollen. Allergy Asthma Proc 33:27-35, 2012.
16. Mohar DE, Berger W, Laforce C, et al. Efficacy and tolerability study of ciclesonide nasal aerosol in patients with perennial allergic rhinitis. Allergy Asthma Proc 33:19-26, 2012.
17. Food and Drug Administration. Guidance for Industry, Allergic Rhinitis: Clinical Development. Food and Drug Administration April 2000 1;1-19. Accessed January 28, 2012.
18. World Medical Association. Declaration of Helsinki. Helsinki, Finland. Ethical principles for medical research involving human subjects. 2008.
19. Van AA, Bronsky EA, Dockhorn RJ, et al. Once daily fluticasone propionate is as effective for perennial allergic rhinitis as twice daily beclomethasone diproprionate. J Allergy Clin Immunol 91:1146-1154, 1993. (Pubitemid 23173182)
20. Drouin M, Yang WH, Bertrand B, et al. Once daily mometasone furoate aqueous nasal spray is as effective as twice daily beclomethasone dipropionate for treating perennial allergic rhinitis patients. Ann Allergy Asthma Immunol 77:153-160, 1996. (Pubitemid 26274993)
21. Mandl M, Nolop K, and Lutsky BN. Comparison of once daily mometasone furoate (Nasonex) and fluticasone propionate aqueous nasal sprays for the treatment of perennial rhinitis. The 194-079 Study Group. Ann Allergy Asthma Immunol 79:237-245, 1997. (Pubitemid 27499978)
22. Rosenblut A, Bardin PG, Muller B, et al. Long-term safety of fluticasone furoate nasal spray in adults and adolescents with perennial allergic rhinitis. Allergy 62:1071-1077, 2007. (Pubitemid 47220982)
23. Juniper EF, and Guyatt GH. Development and testing of a new measure of health status for clinical trials in rhinoconjunctivitis. Clin Exp Allergy 1:77-83, 1991.
24. Juniper EF, Thompson AK, Ferrie PJ, and Roberts JN. Validation of the standardized version of the Rhinoconjunctivitis Quality of Life Questionnaire. J Allergy Clin Immunol (2 Pt 1):364-369, 1999. (Pubitemid 29420434)